Official ESCRS | European Society of Cataract & Refractive Surgeons


Safety and efficacy of iStent Inject® trabecular micro-bypass stents during phacoemulsification for open-angle glaucoma associated with cataract

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Glaucoma II

Venue: Poster Village: Pod 3

First Author: : D.Cela FRANCE

Co Author(s): :    E. Brasnu   P. Hamard   C. Baudouin   A. Labbé              

Abstract Details


The aim of this study was to assess the efficacy and safety of phacoemulsification combined with iStent Inject® (comprised of 2 stents) implantation for the treatment of open-angle glaucoma associated with cataract.


iStent Inject® trabecular micro-bypass system is indicated for the reduction of intraocular pressure in mild-to-moderate primary open-angle glaucoma patients who are undergoing concomitant cataract surgery.


This study is a retrospective analysis of patients who underwent phacoemulsification and implantation of iStent Inject®. For all patients, pre- and postoperative characteristics were evaluated including number of medications and IOP. Postoperative visits were scheduled at 7 days and 1 month after surgery. Ongoing follow-up will continue with an aim to present more cases and longer follow-up outcomes by the time of the presentation.


Forty-one eyes of 31 patients were included in the study. Preoperative mean IOP at baseline was 16.2±4.1 mmHg (range, 10-29 mmHg) with a mean of 2.1±1.0 mmHg medications. After 7 days, the mean IOP was 15.8±4.2 mmHg (range, 10-24 mmHg). At 1 month, the mean IOP was 13.1±3.7 mmHg (range, 5-21) with a mean of 1.8±1.2 antiglaucoma medications. The mean IOP reduction at 1 month was 19.1% (p<0,05) concomitant with a 14% reduction in the mean number of medications. A favorable safety profile with no significant intraoperative or postoperative complications were noted.


Initial outcomes with phacoemulsification combined with implantation of iStent Inject® results in effective IOP reduction in patients with concomitant cataract and open-angle glaucoma. No severe device related side effects were observed.

Financial Disclosure:


Back to previous